Voyager Therapeutics, a clinical-stage gene therapy company based in Lexington, Massachusetts, focuses on developing treatments for severe neurological diseases, including Alzheimer's and ALS. Founded in 2015, it employs 162 people and utilizes its TRACER AAV platform for therapy development.